Clinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adults

Clin Infect Dis. 2015 Apr 15;60(8):1170-5. doi: 10.1093/cid/civ019. Epub 2015 Feb 18.

Abstract

Background: Inactivated influenza vaccines are manufactured using either split-virion or subunit methods. These 2 methods produce similar hemagglutinin antibody responses, but different cellular immune responses.

Methods: We compared the effectiveness of split-virion influenza vaccines to that of subunit influenza vaccines using prospectively collected data from adults aged ≥50 years who sought care for acute respiratory illness during 3 influenza seasons: 2008-2009, 2010-2011, and 2011-2012 using a case-positive, control test-negative study design.

Results: Complete data were available for 539 participants, of whom 68 (12.6%) had influenza detected. Influenza-infected patients were younger (P<.001), were more likely to have received no vaccine or the subunit influenza vaccine than the split-virion vaccine (P<.001), and more likely to have sought care in either the emergency department or the acute care clinic than the hospital (P=.001). Split-virion vaccine effectiveness was 77.8% (95% confidence interval [CI], 58.5%-90.3%) compared with subunit vaccine effectiveness of 44.2% (95% CI, -11.8% to 70.9%), giving a difference in vaccine effectiveness of 33.5% (95% CI, 6.9%-86.7%).

Conclusions: Studies need to be done to further explore if there are differences in clinical effectiveness in older adults for the 2 vaccine manufacturing methods.

Keywords: clinical effectiveness; influenza; older adults; split-virion vaccine; subunit vaccine.

Publication types

  • Observational Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Female
  • Humans
  • Influenza Vaccines / administration & dosage
  • Influenza Vaccines / immunology*
  • Influenza, Human / prevention & control*
  • Male
  • Middle Aged
  • Prospective Studies
  • Treatment Outcome
  • Vaccines, Inactivated / administration & dosage
  • Vaccines, Inactivated / immunology
  • Vaccines, Subunit / administration & dosage
  • Vaccines, Subunit / immunology

Substances

  • Influenza Vaccines
  • Vaccines, Inactivated
  • Vaccines, Subunit